December 17, 2018

Human Trial for Tosk Drug to Prevent Mucositis Proves Effective, Safe

MOUNTAIN VIEW, CALIFORNIA, USA, December 17, 2018 /EINPresswire.com/ — Privately held biotechnology company, Tosk, Inc., announced today the successful completion of the Company’s human clinical study […]
December 15, 2018

Global Business Reports Interviews Tosk CEO Brian Frenzel on Trials, Partnerships, Progress

Tosk is developing a family of inexpensive, small molecule drugs designed to prevent the toxic side effects of common cancer treatments, resulting in significantly improved patient […]
December 11, 2018

Tosk Presents Jointly on KRAS Project at Research Meeting in San Diego

Mountain View, CA, December 11, 2018   ̶  Privately held biotechnology company, Tosk, Inc., announced today a joint presentation with the US National Cancer Institute (NCI) […]
September 13, 2018

Tosk, Inc. Receives Additional $2 million NCI Grant for Promising KRAS Project

MOUNTAIN VIEW, CALIFORNIA, USA, September 13, 2018 /EINPresswire.com/ — NATIONAL CANCER INSTITUTE RENEWS GRANT FOR TOSK, INC’S, PROMISING CANCER KRAS PROGRAM “Tosk’s scientists are focused on […]
May 15, 2018

The pharmaceutical research company Roots Analysis talks to CEO Brian Frenzel about Tosk’s promising kRAS program.

Roots Analysis: We are aware that Tosk is focused on the development of discovery stage drug candidates targeting KRAS mutations. Can you provide some insights on […]
March 14, 2018

California Drug Developer Tosk, Inc. Announces Two Milestones for Transformational Cancer Treatment

Tosk, Inc., marks six months of significant human trials of drug eliminating toxic effects of common cancer therapies, grant by National Cancer Institute (NCI). MOUNTAIN VIEW, […]
December 12, 2017

Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.

TK-39, Tosk’s second patented product, which blocks damage to the heart (cardiotoxicity) resulting from widely used cancer drugs known as anthracyclines, has proved preclinical efficacy testing […]
December 1, 2017

Tosk has had excellent though preliminary results of its recently inaugurated human trials for its TK-90 drug, which protects against mucositis.

Tosk has initiated human trials for its TK-90 drug, and preliminary results are encouraging. The drug is intended to reduce or eliminate the side effects of […]
July 15, 2017

Tosk Reports Initiation of POC Human Studies

MOUNTAIN VIEW, CA, JULY 19, 2017 Tosk, Inc. reported today the completion of Phase 1 safety trials and the initiation of POC studies in human cancer […]